Velindre Library
@vcclibrary.bsky.social
Velindre University NHS Trust Library, the only cancer specialist library service in Wales. Supporting NHS and academic staff, students and health professionals.
Reposted by Velindre Library
📣 We're rounding up a few dates for your diary. Discover these events being run by our global network of Cochrane Groups.
Discover them below – 🧵
Discover them below – 🧵
January 31, 2026 at 2:22 PM
📣 We're rounding up a few dates for your diary. Discover these events being run by our global network of Cochrane Groups.
Discover them below – 🧵
Discover them below – 🧵
Fresh listening for your ears! Immunobuddies Episode 179: Impact of Diet on Immunotherapy and Practical Approaches Part 3 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/6T4t...
Episode 179: Impact of Diet on Immunotherapy and Practical Approaches Part 3 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby
open.spotify.com
January 30, 2026 at 10:47 AM
Fresh listening for your ears! Immunobuddies Episode 179: Impact of Diet on Immunotherapy and Practical Approaches Part 3 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/6T4t...
Post-traumatic growth related to long-term follow up in survivors of childhood #Cancer: a national qualitative study. link.springer.com/article/10.1...
link.springer.com
January 30, 2026 at 10:22 AM
Post-traumatic growth related to long-term follow up in survivors of childhood #Cancer: a national qualitative study. link.springer.com/article/10.1...
Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal #Cancer @healthtechwales.bsky.social @velindrecc.bsky.social healthtechnology.wales/reports-guid...
Capsule sponge devices - Health Technology Wales
healthtechnology.wales
January 30, 2026 at 10:18 AM
Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal #Cancer @healthtechwales.bsky.social @velindrecc.bsky.social healthtechnology.wales/reports-guid...
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced #BreastCancer. www.nejm.org/doi/full/10....
www.nejm.org
January 29, 2026 at 2:23 PM
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced #BreastCancer. www.nejm.org/doi/full/10....
Breaking bad news and the cost of caring on physicians: a systematic scoping review. spcare.bmj.com/content/earl...
Breaking bad news and the cost of caring on physicians: a systematic scoping review
Background Caring for dying patients and their distressed families can be traumatic. For physicians, these encounters shape the way they see, act and feel as professionals, influencing the inculcation...
spcare.bmj.com
January 29, 2026 at 2:17 PM
Breaking bad news and the cost of caring on physicians: a systematic scoping review. spcare.bmj.com/content/earl...
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx #Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
January 29, 2026 at 1:56 PM
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx #Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. ascopubs.org/doi/10.1200/...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive #BreastCancer: The Randomized Noninferiority Phase III neoCARHP Trial. ascopubs.org/doi/10.1200/...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Tria...
PURPOSEThe neoCARHP aimed to investigate the efficacy and safety of investigator-selected
taxane (docetaxel, paclitaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab,
with carboplatin (TCbHP) or...
ascopubs.org
January 29, 2026 at 1:55 PM
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive #BreastCancer: The Randomized Noninferiority Phase III neoCARHP Trial. ascopubs.org/doi/10.1200/...
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic #BreastCancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
January 29, 2026 at 1:53 PM
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic #BreastCancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. ascopubs.org/doi/10.1200/...
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). ascopubs.org/doi/10.1200/...
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
PURPOSEImmune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much
lower than standard approved doses. We hypothesized that ultra-low-dose nivolumab
would retain clinical efficac...
ascopubs.org
January 29, 2026 at 1:46 PM
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). ascopubs.org/doi/10.1200/...
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma. www.esmoopen.com/article/S205...
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma
This first-in-human phase I/IIa study evaluated auceliciclib, a second-generation,
highly selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor with potent antitumour
activity, high brain penetrati...
www.esmoopen.com
January 29, 2026 at 12:59 PM
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma. www.esmoopen.com/article/S205...
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal #Cancer (TACTIC CRC-02): a phase II study. www.esmoopen.com/article/S205...
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized
immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined
with standard XELOX plu...
www.esmoopen.com
January 29, 2026 at 12:57 PM
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal #Cancer (TACTIC CRC-02): a phase II study. www.esmoopen.com/article/S205...
Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck #Cancer: a multicenter, multinational study. www.esmoopen.com/article/S205...
Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study
Head and neck squamous-cell carcinoma (HNSCC) accounts for ∼5.3% of cancer-related
mortality worldwide, with an estimated 890 000 new diagnoses and 450 000 deaths annually.
Despite curative-intent the...
www.esmoopen.com
January 29, 2026 at 12:54 PM
Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck #Cancer: a multicenter, multinational study. www.esmoopen.com/article/S205...
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. www.annalsofoncology.org/article/S092...
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
Therapeutic options after progression on EGFR tyrosine kinase inhibitors (TKIs) remain
limited for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Izalontamab
brengitecan (Iza-bren; BL-...
www.annalsofoncology.org
January 29, 2026 at 12:49 PM
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. www.annalsofoncology.org/article/S092...
A robustness-inclusive comparison of proton- versus photon-based whole-pelvic radiotherapy for #ProstateCancer within a randomised clinical trial. www.thegreenjournal.com/article/S016...
A robustness-inclusive comparison of proton- versus photon-based whole-pelvic radiotherapy for prostate cancer within a randomised clinical trial
Whole-pelvic radiotherapy (WPRT) is a strategy aimed at treating microscopic lymphatic
spread for patients with high-risk prostate cancer [1]. While WPRT improves disease
control compared to prostate-...
www.thegreenjournal.com
January 29, 2026 at 9:43 AM
A robustness-inclusive comparison of proton- versus photon-based whole-pelvic radiotherapy for #ProstateCancer within a randomised clinical trial. www.thegreenjournal.com/article/S016...
Healthcare systems data (HSD) to improve the efficiency of clinical trials within the UK: A prospectively planned comparison of HSD and trial-reported outcomes within the Add-Aspirin #Cancer clinical trial. www.clinicaloncologyonline.net/article/S093...
Healthcare systems data (HSD) to improve the efficiency of clinical trials within the UK: A prospectively planned comparison of HSD and trial-reported outcomes within the Add-Aspirin cancer clinical t...
Healthcare systems data (HSD) can potentially improve the efficiency and costs of
clinical trials (CTs) and reduce the burden of follow-up. To be used in CTs, HSD need
to be accessible, accurate and c...
www.clinicaloncologyonline.net
January 29, 2026 at 9:36 AM
Healthcare systems data (HSD) to improve the efficiency of clinical trials within the UK: A prospectively planned comparison of HSD and trial-reported outcomes within the Add-Aspirin #Cancer clinical trial. www.clinicaloncologyonline.net/article/S093...
New Immunobuddies episode alert! Episode 178: Impact of Diet on Immunotherapy and Practical Approaches Part 2 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/0iWQ...
Episode 178: Impact of Diet on Immunotherapy and Practical Approaches Part 2 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby
open.spotify.com
January 23, 2026 at 11:19 AM
New Immunobuddies episode alert! Episode 178: Impact of Diet on Immunotherapy and Practical Approaches Part 2 with Immunotherapy Dietician Raiatea Van-Reenen University Hospital Derby @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/0iWQ...
Internal validation protocol for large collaborative clinical data sets: assessment of the CONGRESS database – Annals of the Royal College of Surgeons of England. @velindrecc.bsky.social publishing.rcseng.ac.uk/doi/10.1308/...
Internal validation protocol for large collaborative clinical data sets: assessment of the CONGRESS database | The Annals of The Royal College of Surgeons of England
Introduction Multicentre clinical research collaboratives collect large, generalisable data sets. However, data are often collected by trainees who may lack clinical or academic experience, raising co...
publishing.rcseng.ac.uk
January 23, 2026 at 11:10 AM
Internal validation protocol for large collaborative clinical data sets: assessment of the CONGRESS database – Annals of the Royal College of Surgeons of England. @velindrecc.bsky.social publishing.rcseng.ac.uk/doi/10.1308/...
NICE Technology Appraisal Guideline [TA1122]: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell #LungCancer www.nice.org.uk/guidance/ta1...
Overview | Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer | Guidance | NICE
www.nice.org.uk
January 23, 2026 at 11:02 AM
NICE Technology Appraisal Guideline [TA1122]: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell #LungCancer www.nice.org.uk/guidance/ta1...
Consolidation Chemotherapy after Preoperative Chemoradiotherapy for Locally Advanced Rectal #Cancer: 7-Year Follow-Up Results of a Randomized Multicenter Trial (KCSG CO 14-03) www.redjournal.org/article/S036...
Consolidation Chemotherapy after Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: 7-Year Follow-Up Results of a Randomized Multicenter Trial (KCSG CO 14-03)
Total neoadjuvant therapy (TNT) has become the standard treatment for locally advanced
rectal cancer (LARC). However, the optimal sequence and duration of treatment remain
unclear. Hence, the long-ter...
www.redjournal.org
January 23, 2026 at 10:51 AM
Consolidation Chemotherapy after Preoperative Chemoradiotherapy for Locally Advanced Rectal #Cancer: 7-Year Follow-Up Results of a Randomized Multicenter Trial (KCSG CO 14-03) www.redjournal.org/article/S036...
Phase I Clinical Trial of De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Advanced Endometrial #Cancer (DeCRESCEndo). www.redjournal.org/article/S036...
Phase I Clinical Trial of De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Advanced Endometrial Cancer (DeCRESCEndo)
The safety and efficacy of hypofractionated-radiation (hypo-RT) and chemotherapy for
locally advanced endometrial cancer is unknown. We evaluated the safety of hypo-RT
sequenced after chemotherapy for...
www.redjournal.org
January 23, 2026 at 10:49 AM
Phase I Clinical Trial of De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Advanced Endometrial #Cancer (DeCRESCEndo). www.redjournal.org/article/S036...
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative Radiotherapy www.redjournal.org/article/S036...
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative Radiotherapy
Stereotactic ablative body radiotherapy (SABR) is an emerging indication for localized
renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices,
as accurate target deline...
www.redjournal.org
January 23, 2026 at 10:35 AM
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative Radiotherapy www.redjournal.org/article/S036...
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic #cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial. www.redjournal.org/article/S036...
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial
The use of SABR for oligometastatic cancer is expanding, but prospective long-term
survival data are limited. This study reports long-term secondary outcomes of overall
survival (OS), progression-free...
www.redjournal.org
January 23, 2026 at 10:29 AM
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic #cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial. www.redjournal.org/article/S036...
Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized #ProstateCancer. www.thegreenjournal.com/article/S016...
Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer
Prostate cancer remains one of the most commonly diagnosed malignancies among men
worldwide, with a wide spectrum of therapeutic options tailored to disease risk, patient
comorbidities, and personal p...
www.thegreenjournal.com
January 23, 2026 at 10:25 AM
Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized #ProstateCancer. www.thegreenjournal.com/article/S016...
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data. www.thegreenjournal.com/article/S016...
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
Follicular lymphoma (FL) is exquisitely radiosensitive [1–4] and definitive radiotherapy
(RT) has long been the standard treatment for early-stage FL (ESFL, stage I-II). Despite
durable local disease ...
www.thegreenjournal.com
January 23, 2026 at 10:20 AM
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data. www.thegreenjournal.com/article/S016...